Incidence and Impact of Parvovirus B19 Infection in Seronegative Solid Organ Transplant Recipients.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33458766.
- Also identified by DOI 10.1093/infdis/jiab024.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Routine monitoring of parvovirus B19 (B19V) the first 6 months posttransplantation was performed in 241 seronegative solid organ transplant (SOT) recipients. Incidence rates during the first month and the second to sixth months posttransplantation were 1.2 (95% confidence interval [CI], .33-3.2) and 0.21 (95% CI, .06-.57) per 100 recipients per month, respectively. Of the 6 SOT recipients with positive B19V polymerase chain reaction, 3 (50%) were admitted to hospital and 2 (33%) were treated with intravenous immunoglobulin. Thus, routine monitoring of B19V in seronegative SOT recipients may not be necessary. Targeted screening 1 month posttransplantation and screening upon clinical suspicion could be an alternative strategy.
Medical subject headings
- Immunocompromised Host
- Organ Transplantation
- Parvoviridae Infections
- Parvovirus B19, Human